Form 4: OptimizeRx Chief Commercial Officer Reports Stock Transactions

OptimizeRx's Chief Commercial Officer, Stephen L. Silvestro, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reported transactions involving the company's stock.
• On December 19, 2024, 6,546 restricted stock units vested and converted into common stock.
• Simultaneously, 2,576 shares were sold at $4.75 per share to cover tax withholding obligations.
• Following these transactions, Silvestro directly owns 80,848 shares of OptimizeRx common stock and 13,093 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions related to compensation, which is neither positive nor negative for the company's overall performance. It is a neutral event.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent sale for tax obligations is a standard practice in executive compensation across the industry.
• Many companies use similar vesting schedules for their equity grants, typically over a 3-4 year period.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are related to executive compensation and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

OptimizeRx, OPRX, stock transaction, restricted stock units, insider trading, Form 4, Stephen L. Silvestro, Chief Commercial Officer